Reaching Others University at Buffalo - The State University of New York
Skip to Content
Official UB news and information for the media

UB, Empire Genomics partner with Life Technologies to accelerate innovative, genetics-based clinical research in Western New York

Collaboration will strengthen regional life sciences industry

Release Date: June 5, 2013

“Genetics-based diagnostics will play a major role in developing personalized medicine, and that in turn will create new job opportunities in Western New York.”
Norma J. Nowak
Founder and chief scientific officer at Empire Genomics and director of science and technology at UB’s New York State Center of Excellence in Bioinformatics and Life Sciences

BUFFALO, N.Y. and CARLSBAD, Calif. —  Empire Genomics, Life Technologies Corporation (NASDAQ: LIFE) and the University at Buffalo will embark on a new partnership to develop world-class gene sequencing facilities for genetics-based clinical research on the Buffalo Niagara Medical Campus.

The collaboration capitalizes on each organization’s strengths to help establish a new standard for genomic research in Western New York and continue to grow the life sciences sector of the region’s economy.

Life Technologies, a global provider of biotechnology products and services, will provide state-of-the-art genome sequencing equipment enabling UB and Empire Genomics to establish their initial set up of Clinical Laboratory Improvement Amendments (CLIA)-certified sequencing facilities on the Buffalo Niagara Medical Campus.

The advanced sequencing technology available from Life Technologies, combined with the expertise of UB researchers and the Empire Genomics team, will help clinical researchers develop new diagnostic tests that, in the future, could enable physicians to prescribe treatments tailored to each individual based on genetic make-up.

“We are very pleased that after carefully looking at all of the alternatives, the University at Buffalo and Empire Genetics decided that Ion semiconductor sequencing was the best platform to help them reach their goal of advancing genetics-based clinical research, and ultimately driving growth in the life sciences industry in Western New York,” said Mark Stevenson, president and chief operating officer at Life Technologies.

Achieving CLIA certification will enhance and expand the services Empire Genomics and UB provide to clients across the globe, and holds the promise of spawning new diagnostic tests for a number of diseases or conditions. The results will eventually lead to new tools to deliver better health care while growing new jobs in Western New York.  

“This collaboration is a great example of the impact that can be made when industry and academic partners work together toward shared goals,” said Marnie LaVigne, PhD, associate vice president for economic development at UB. “We look forward to continuing to partner with Life Technologies and Empire Genomics on these efforts to support the advancement of genetics-based clinical research and the life sciences as key economic drivers in our region.”

The CLIA-certified laboratories will be set up at UB’s New York State Center of Excellence in Bioinformatics and Life Sciences and at the downtown Buffalo headquarters of Empire Genomics, a provider of genetics-based research and testing services.  

“Genetics-based diagnostics will play a major role in developing personalized medicine, and that in turn will create new job opportunities in Western New York,” said Norma J. Nowak, PhD, founder and chief scientific officer at Empire Genomics and director of science and technology at UB’s New York State Center of Excellence in Bioinformatics and Life Sciences. “Leveraging our combined strengths will ensure that we remain at the forefront of technological and research capabilities while making greater long-term contributions to the public health.”

About Empire Genomics, LLC

Empire Genomics delivers the most advanced genomic tools to facilitate the scientific community in its research and diagnostic challenges. Through many years of experience in the area of genomics and working with diverse sample types, Empire Genomics is able to provide continuous innovation for research and diagnostic applications in areas of oncology, biomarkers, drug discovery, constitutional disorders, developmental disorders and autism, among many others.

About the NYS Center of Excellence in Bioinformatics and Life Sciences at UB

The mission of the University at Buffalo’s New York State Center of Excellence in Bioinformatics and Life Sciences is to foster economic development by connecting university resources with life sciences and high-tech industry through funding, research and development support, programming and education, with the goal of helping companies find business solutions, accelerate new ideas and grow. This technology-based economic development mission is complemented by the center’s efforts to support the advancement of new discoveries in science that seek better ways of preventing and managing disease and improving lives. Learn more at: www.bioinformatics.buffalo.edu.

About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions are secured by more than 5,000 patents and licenses that span the entire biological spectrum — scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research. Life Technologies has approximately 10,000 employees and had sales of $3.8 billion in 2012. Visit us at our website: http://www.lifetechnologies.com.

Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

All products referenced are for Research Use Only and not intended for use in diagnostic procedures, unless otherwise noted.

Media Contact Information